Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy

Journal of Diabetes and Metabolic Disorders

Volumn 13, Issue 1, 2014, Pages

  Tripathi, Alok S ^a   Mazumder, Papiya M ^b   Chandewar, Anil V ^a  

^a PWadhwani College Of Pharmacy   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Diabetic nephropathy; Sildenafil citrate; Streptozotocin

Indexed keywords

SILDENAFIL; STREPTOZOCIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UREA NITROGEN BLOOD LEVEL;

EID: 84908145818     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/2251-6581-13-8     Document Type: Article

References (42)

1. Melmed S, Polonsky SK, Larsen PR, Kronenberg HM. Williams textbook of endocrinology 1371-1435. Philadelphia: Elsevier/Saunders, 12, 978-1-4377-0324-5.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5):1047-1053. 10.2337/diacare.27.5.1047, 15111519.
3. Gale J. India's Diabetes Epidemic Cuts Down Millions Who Escape Poverty 2010, Retrieved: Bloomberg, 2012.
4. McGill M, Felton AM. New global recommendations: a multidisciplinary approach to improving out comes in diabetes. Prim Care Diabetes 2007, 1:49-55. 10.1016/j.pcd.2006.07.004, 18632019.
5. Ueyama J, Wang D, Kondo T, Saito I, Takagi K, Takagi K, et al. Toxicity of diazinon and its metabolites increases in diabetic rats. Toxicol Lett 2007, 170:229-237. 10.1016/j.toxlet.2007.03.010, 17442507.
6. Liu X, Tang D, Yin X, Gao Y, Wei Y, Chen Y. Pharmacokinetic study of rutin in normal and diabetic nephropathy rats. Acta Acad Med Xuzhou 2009, 29:708-712.
7. Qin H, Duan H, Wei Y, Zhang D, Li B, Wu X. Comparison on the pharmacokinetic of metformin hydrochloride between normal and diabetic rats. Chin J Mod Appl Pharm 2009, 26:433-436.
8. Wu K. Pharmacokinetics comparison of berberine in gengenqinlian detection between normal rats and diabetic rats. China Pharm 2010, 13:467-468.
9. Parsons RL. Drug absorption in gastrointestinal disease with particular reference to mal absorption syndromes. Clin Pharmacokinet 1977, 2:45-60. 10.2165/00003088-197702010-00004, 322910.
10. Nowicki MT, Aleksunes LM, Sawant SP, Dnyanmote AV, Mehendale HM, Manautou JE. Renal and hepatic transporter expression in type2 diabetic rats. Drug Metab Lett 2008, 2:11-17. 10.2174/187231208783478425, 19356064.
11. Shimojo N, Ishizaki T, Imaoka S, Funae Y, Fujii S, Okuda K. Changes in amounts of cytochrome P450 isozyme sand levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin- induced diabetes. Biochem Pharmacol 1993, 46:621-627. 10.1016/0006-2952(93)90547-A, 8363636.
12. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006, 109:1-11. 10.1016/j.pharmthera.2005.05.010, 16085315.
13. Charpentier G, Riveline JP, Varroud VM. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000, 26:73-85.
14. Xiaoyan X, Bin M. Cellular and humonal immune responses in the early stage of diabetic nephropathy. J Autoimmnity 2009, 32:85-93.
15. Saisho K, et al. Extraction and determination of sildenafil (Viagra) and its N-desmethyl metabolite in rat and human hair by GC-MS. Biol Pharm Bull 2001, 24:1384-1388. 10.1248/bpb.24.1384, 11767107.
16. Kuno Y, Iyoda M, Shibata T, Hirai Y, Akizawa T. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long- Evans Tokushima Fatty rats. Br J Pharmacol 2011, 162(6):1389-1400. 10.1111/j.1476-5381.2010.01149.x, 3058170, 21133896.
17. Tripathi AS, Sheikh I, Dewani AP, Shelke PG, Bakal RL, Chandewar AV, Mazumder PM. Development and validation of RP-HPLC method for sildenafil citrate in rat plasma-application to pharmacokinetic studies. Saudi Pharm J 2012, 21:317-321. 3745091, 23960848.
18. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 1992, 44:103-150.
19. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984, 74:1143-1155. 10.1172/JCI111523, 425280, 6480821.
20. Salonia P, Rigatti F, Montorsi P. Sildenafil in erectile dysfunction: a critical review. Curr Med Res Opin 2003, 19:241. 10.1185/030079903125001839, 12841917.
21. Langtry HD, Markham A. Sildenafil: a review of its Use in erectile dysfunction. Drugs 1999, 57:967. 10.2165/00003495-199957060-00015, 10400408.
22. Croom KF, Curran MP. Sildenafil: a review of its Use in pulmonary arterial hypertension. Drugs 2008, 68:383. 10.2165/00003495-200868030-00009, 18257613.
23. Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002, 1:674. 10.1038/nrd893, 12209148.
24. Montani D, Chaumais MC, Savale S, Natali D, Price LC, Jais X, Humbert M, Simonneau G, Sitbon O. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension Adv. Ther. 2009, 26:813.
25. Meibohm B, Mehrotra N, Gupta M, Kovar A. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007, 19:253. 10.1038/sj.ijir.3901522, 16988721.
26. Cohen MP, Ziyadeh FN, Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med 2006 May, 147(5):211-219.
27. Day JF, Thorpe SR, Baynes JW. Nonenzymatically glucosylated albumin: in vitro preparation and isolation from normal human serum. J Biol Chem 1979 Feb 10, 254(3):595-597.
28. Ruiz-Cabello F, Erill S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 1984 Nov, 36(5):691-695.
29. Worner W, Preissner A, Rietbrock N. Drug-protein binding kinetics in patients with type I diabetes. Eur J Clin Pharmacol 1992, 43(1):97-100. 10.1007/BF02280763, 1380461.
30. Kearns GL, Kemp SF, Turley CP, et al. Protein binding of phenytoin and lidocaine in pediatric patients with type I diabetes mellitus. Dev Pharmacol Ther 1988, 11(1):14-23.
31. Kemp SF, Kearns GL, Turley CP. Alteration of phenytoin binding by glycosylation of albumin in IDDM. Diabetes 1987 Apr, 36(4):505-509.
32. Trovik TS, Jaeger R, Jorde R, et al. Plasma protein binding of catecholamines, prazosin and propranolol in diabetes mellitus. Eur J Clin Pharmacol 1992, 43(3):265-268. 10.1007/BF02333020, 1425889.
33. Trovik TS, Jaeger R, Jorde R, et al. Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness. Br J Clin Pharmacol 1994 Nov, 38(5):427-432.
34. Reidenberg MM, Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984 Jan, 9(Suppl. 1):18-26.
35. Keller F, Maiga M, Neumayer HH, et al. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet 1984, 9(3):275-282. 10.1007/BF03189651, 6519129.
36. Gatti G, Crema F, Attardo-Parrinello G, et al. Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther Drug Monit 1987 Dec, 9(4):389-391.
37. McNamara PJ, Blouin RA, Brazzell RK. The protein binding of phenytoin, propranolol, diazepam, and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res 1988 May, 5(5):261-265.
38. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (part II). Clin Pharmacokinet 1990 Sep, 19(3):218-229.
39. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels: implications for drug dosage regimens (part I). Clin Pharmacokinet 1990 Aug, 19(2):147-159.
40. Okabe N, Hashizume N. Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol Pharm Bull 1994 Jan, 17(1):16-21.
41. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991 Jun, 20(6):477-490.
42. Thomas S. Diabetic nephropathy. Medicine 2010, 12(38):639-643.